Drug
Faricimab clinical trials
Also written RO6867461, VABYSMO™ and RG7716.
- studies test it
- 44
- open now
- 19
- in phase 3
- 15
- first study started
- 2006
Keep track of what changes. Save the faricimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- VABYSMO™
- 13
Combined with it in one product
Studies by the year they started
44 studies that test it; most in 2026 (8)
| Year | Studies |
|---|---|
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 5 |
| 2025 | 7 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 10
- Phase 3
- 15
- Phase 4
- 13
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 27
Hoffmann-La Roche (14) · Genentech, Inc. (3) · Singapore National Eye Centre (2) · Jaeb Center for Health Research (2) · Asociación para Evitar la Ceguera en México (2) · McMaster University (1) · Greater Houston Retina Research (1) · Bojie Hu (1)
Often tested with
Tested in the same studies.
Aflibercept (1) · KH902 fusion protein (1) · Ranibizumab (1) · Bevacizumab (1) · Fluocinolone Acetonide (1)
Studies
Open first, then newest update. How each study uses faricimab is read from its arms, and is right about nine times in ten.
Testing it · 44
- Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation RetinopathyRecruitingPhase 3Jaeb Center for Health ResearchNCT05844982Written as Faricimab
- A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)RecruitingPhase 1Genentech, Inc.NCT07425522Written as Faricimab
- Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDRRecruitingPhase 3Jaeb Center for Health ResearchNCT06790784Written as Faricimab
- Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial SettingRecruitingNot applicableSingapore National Eye CentreNCT07249216Written as Faricimab
- South Asian Patients With Diabetic Macular Oedema Treated With Faricimab Assessing the Efficacy, Durability, and Safety (SEAFAR Study)Not yet recruitingPhase 4Birmingham and Midland Eye Centre Sandwell and west Birmingham NHS trustNCT07753616Written as Intravitreal anti-VEGF injection, Faricimab
- Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular DegenerationRecruitingPhase 4Junyeop LeeNCT07367282Written as Faricimab Injection [Vabysmo]
- A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis SyndromeRecruitingPhase 4Cincinnati Eye Institute, Southwest OhioNCT07695298Written as Faricimab Injection [Vabysmo]
- Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled TrialNot yet recruitingPhase 2Singapore National Eye CentreNCT07681167Written as Faricimab
- Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic RetinopathyEnrolling by invitationPhase 4University of Colorado, DenverNCT06191094Written as Faricimab Injection
- Efficacy of Faricimab in Patients With Subretinal Hyper-reflective MaterialRecruitingPhase 4Biobizkaia Health Research InstituteNCT07403825Written as Vabysmo 6 MG in 0.05 ML Injection
- Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar RanibizumabRecruitingNot applicableOsijek University HospitalNCT07520045Written as Faricimab
- Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal VasculopathyRecruitingPhase 3Yeungnam University College of MedicineNCT07461441Written as Faricimab Injection [Vabysmo]
- Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)RecruitingPhase 4Association for Innovation and Biomedical Research on Light and ImageNCT06709339Written as Faricimab Injection [Vabysmo]
- Faricimab Quarterly Maintenance for Neovascular Age Related Macular DegenerationRecruitingPhase 4Hospital Authority, Hong KongNCT06742307Written as Faricimab Injection [Vabysmo]
- Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular NeovascularizationNot yet recruitingPhase 4Kim's Eye HospitalNCT07187804Written as Intravitreal faricimab injection
- Impact of Intravitreal Faricimab on Renal Function in Diabetic PatientsRecruitingNot applicableUniversity Hospital, AlexandroupolisNCT06929507Written as Intravitreal injection of Faricimab or Aflibercept 2 mg
- Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment IntervalsRecruitingPhase 4Faculty Hospital Kralovske VinohradyNCT06875245Written as Faricimab Injection
- Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO PatientsRecruitingPhase 2/3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06572553Written as Faricimab
- Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural OutcomeRecruitingPhase 2/3Asociación para Evitar la Ceguera en MéxicoNCT00346814Written as intravitreal injection
- A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular EdemaActive, not recruitingPhase 4Genentech, Inc.NCT05224102Written as Faricimab
See all 44 studies that test faricimab →
Given in every arm · 3 — faricimab is usual care beside what is tested
- Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular DegenerationCompletedPhase 4Medical University of GrazNCT05941715Written as Faricimab 120 MG/ML
- A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein OcclusionCompletedPhase 3Hoffmann-La RocheNCT04740931Written as Faricimab
- A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein OcclusionCompletedPhase 3Hoffmann-La RocheNCT04740905Written as Faricimab
As the comparator · 3 — what is tested is compared with faricimab
- A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）Active, not recruitingPhase 2Innovent Biologics Technology Limited (Shanghai R&D Center)NCT06908876Written as Faricimab
- A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324CompletedPhase 1Ollin Biosciences, Inc.NCT07484074Written as Faricimab
- PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DMECompletedPhase 3Rush Eye AssociatesNCT03660345Written as Intravitreal injection
Codes
What other systems call faricimab · ClinicalTrials.gg INT001944
- MeSH (NLM) C000723200faricimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) QC4F7FKK7IFARICIMABConfirmed FDA, NLM, Wikidata
- RxNorm 2591519One source FDA
- Wikidata Q60785557faricimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174885FaricimabOne source FDA
- DrugBank DB15303One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723200 | faricimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | QC4F7FKK7I | FARICIMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2591519 | — | One source FDA |
| Wikidata | Q60785557 | faricimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174885 | Faricimab | One source FDA |
| DrugBank | DB15303 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.